Business Wire

Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations

Share

Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

The FLEX study is led by clinicians across the United States and utilizes a shared study infrastructure to develop and investigate hypotheses for targeted patient subsets based on full transcriptome data, and annotated with over 800 clinical data elements. FLEX allows for diverse groups of patients and their physicians to participate in a clinical trial even if they are not living near a major research center.

“FLEX has continued to show its value in the enormous breadth of growing data we as oncologists and researchers can access,” said Cynthia X. Ma, MD, PhD, oncologist and FLEX national PI at Washington University School of Medicine in St. Louis. “The collaborative nature of the registry gives physicians the chance to investigate the hypotheses formed in our real-world practices on a national level, to answer questions of both clinical importance and scientific interest. The depth and clinical significance of our findings are felt throughout the breast cancer community.”

At the virtual ASCO 2021 conference, Agendia and its research collaborators provided a general update on the currently enrolling FLEX trial in a poster titled “The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer.”

The power of FLEX to address relevant and pressing clinical questions was illustrated by data presented in a poster entitled “Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients <50 years and >50 years.” The study showed that whole transcriptome analysis identified no substantial differences in gene expression between HR+/HER2- tumors in women with breast cancer, regardless of their age (over or under 50 years old). The data support the likely explanation that the apparent age-dependent benefit of chemotherapy in women younger than 50 with genomically Low Risk cancer, observed in recent trials, is not due to intrinsic biological differences in breast cancer, but rather to differences in the indirect effects of chemotherapy on the patient. These findings reinforce the essential need for shared decision making between a patient and her physician using the patient’s genomic expression profile as part of an informed treatment plan.

“We are excited to present an age-based analysis of the genomics in early stage breast cancer which has garnered so much attention in the last couple of years,” said Cathy Graham, MD, FACS, Director of Breast Surgery, Glenn Family Breast Center of Winship Cancer Institute at Emory Saint Joseph's Hospital, and first author of a FLEX poster focused on age-based analysis. “The trend that has emerged, which suggests that chemotherapy benefit seen in younger women may be a side effect of ovarian suppression – not necessarily the cytotoxic effects of the chemo on a tumor – is seen again in these results and must be considered when potentially less-aggressive alternatives are available.”

Additional data of clinical significance for high risk ER+ breast cancer were presented by FLEX investigators including Joyce O’Shaughnessy, MD, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network, and a member of the Scientific Advisory Board for US Oncology Research Network, in the poster titled Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the 80-gene signature.” This study outlined the identification by BluePrint of a subgroup of high risk ER+ tumors that are genomically Basal, and showed that analysis of whole transcriptome expression profiles reveals these cancers to be biologically closer to ER- Basal (and triple negative breast cancer) than ER+ Luminal cancers. ER+ Basal tumors may therefore require more aggressive treatment than ER+ Luminal tumors, confirming that BluePrint provides clinically actionable information beyond pathological subtyping and may guide neoadjuvant treatment decisions.

A further study from the FLEX database analyzed the correlation between a traditional poor prognosis pathology feature, lymphovascular invasion (LVI), and gene expression patterns. The study, titled Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer,” was presented by Nina D’Abreo, MD, medical director, breast program, Winthrop University Hospital, Perlmutter Cancer Center, and her colleagues, and showed that the potential prognostic information gained from the presence or absence of lymphovascular invasion (LVI) gene expression is likely already captured by MammaPrint and BluePrint. Importantly, presence or absence of LVI in MammaPrint Low Risk cancers was not associated with any discernible differences in whole transcriptome gene expression. LVI is currently excluded from most breast cancer clinical risk assessments, and while further studies will assess clinical outcomes, these data suggest that MammaPrint and BluePrint may be able to address a current gap in stratification of early stage breast cancers.

Agendia’s large-scale, prospective FLEX study continues to provide a rich source of data from real-world evidence in one of the most dynamic and inclusive study designs in breast cancer research to date, underscoring the company’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients.

About Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Walton Enters the Single-Family Build-to-Rent Market Using its 81,000 Acre Land Portfolio Throughout the U.S.23.6.2021 16:18:00 EEST | Press release

Walton Global Holdings has launched a build-to-rent (BTR) line of business that will leverage its more than 81,000 acres of land assets throughout the U.S. to create near-term opportunities for single-family home rental developments. Walton is a global real estate investment and land asset management company with US$3.4 billion under management making the company one of the largest pure-play residential landowners in North America. The launch of Walton’s BTR business provides the company with an immediate competitive advantage during a time when established land parcels are hard to come by for many organizations in this market. Walton’s core products have been pre-development land and land development for more than 42 years. Through its core business, Walton specializes in land acquisition to zoning and entitlements partnering with top national homebuilders throughout the U.S. Walton has already identified 17 near-term opportunities and is in advanced negotiations with a select group o

A European Leader in Retail for Automotive Launches Its Data Exchange Platform Powered by Dawex23.6.2021 16:00:00 EEST | Press release

Dawex, the leading data exchange and data marketplace technology company, today announced a European leader in retail for automotive has chosen Dawex technology to deploy its Data Exchange Platform to distribute, exchange and commercialize data products securely, in compliance with regulations. Relying on Dawex technology, the Data Exchange facilitates access to data products, accelerates data circulation and monetization, and orchestrates a data ecosystem. This data hub enables the entire sector to propose new services, improve productivity and efficiency, mitigate risk, and generate new revenue streams. Our customer’s Data Marketplace empowers participating organizations to build strong data partnerships where data providers and data acquirers benefit from the appropriate governance models to ensure participants remain in full control over the data they share, with whom they share it with, and for which usage. Dawex Data Exchange technology brings the technical, contractual, financia

Sevan Named Great Place to Work® 8 Years in a Row23.6.2021 16:00:00 EEST | Press release

For the eighth year in a row, Sevan Multi-Site Solutions, Inc. (Sevan), a leader in delivering innovative design, program management, construction services and data analytics to organizations with multiple sites, has been recognized as a Great Place to Work®. “Sevan’s culture focuses on people first, which is evident in our renewed status as a Great Place to Work®,” said Jim Evans, President and CEO of Sevan. “Our people are the heart and soul of our business, and their passion for excellence is the reason for our continued success with our clients.” This year a record 92% of Sevan’s team members participated in the Great Place to Work® survey, and over 90% surveyed say Sevan is a great place to work. These team members also say Sevan’s management is honest and ethical, the company contributes positively to the community and that Sevan is an organization they are proud to work for. “Certified companies put employees first,” said Michael C. Bush, CEO at Great Place to Work. “Thriving em

IDEMIA Brings Boarding Security to Los Angeles International Airport (LAX)23.6.2021 16:00:00 EEST | Press release

IDEMIA is facilitating a facial recognition system to help U.S. Customs and Border Protection (CBP) increase air passengers’ security and border control at Los Angeles International Airport (LAX), one of the busiest airports in the world. The technology has been deployed in LAX’s new West Gates at Tom Bradley International Terminal and is a one-stop safety solution for passengers, airlines, and airports alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005420/en/ (Photo: Business Wire) The deployment is part of a contract awarded by Los Angeles World Airports (LAWA) to EASIER, a leader in e-gate technology. In alignment with protection measures defined by the U.S. Congress, passengers will now get to experience a faster, more accurate, and touchless boarding experience. LAX is just one of multiple airports where IDEMIA’s facial recognition technology is deployed in conjunction with CBP and an example of the long-te

Leading Liver Disease Researchers Present at EASL International Liver Congress™ 2021, Demonstrate Prognostic Value of Echosens’ FibroScan-based Agile Scores for Patients with Liver Disease23.6.2021 15:53:00 EEST | Press release

Echosens, a high-technology company offering the FibroScan family of products, today announces that distinguished researchers will present studies supporting the value of FibroScan at EASL’s International Liver Congress, June 23-26, 2021. An area of focus will be FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. “Agile scores were built on a large and global pool of patient data and have been externally validated on two large cohorts of patients—one from France and one from the United States—to achieve this exceptional level of score development,” says Dominique Legros, Group CEO, Echosens. “These novel, noninvasive scores reduce the number of false positive cases compared to liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE™) alone, accurately predict liver complications and, in coming years, will identify patients eligible for pharmaceutical treatments.” Currently a

Sherlock Biosciences’ 221b Foundation Enables Global Access to COVID-19 Diagnostics with Up To 10 Million Tests Per Month23.6.2021 15:30:00 EEST | Press release

The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that its partnerships will increase COVID-19 diagnostic manufacturing capacity by up to 10 million tests per month by year-end. Through multiple license agreements this year with organizations including ALBOT Technologies, Cooper International, LogicInk, Rokline, United PPE and binx health, The 221b Foundation has enabled manufacturing and global distribution in the U.S., United Arab Emirates, India and Singapore, and is in discussions to expand beyond these geographies to increase access for vital diagnostic solutions around the world. The 221b Foundation was founded to aid in the fight against the global COVID-19 pandemic by enabling access to intellectual property associated with the company’s SHERLOCK™ CRISPR-based technology. Proceeds from third-party sales of SHERLOCK CRISPR COVID-19 products have

Tarjousasiakirja koskien Adapteo Oyj:n hallituksen suosittelemaa julkista käteisostotarjousta Adapteo Oyj:n osakkeenomistajille on julkaistu23.6.2021 15:00:00 EEST | Tiedote

Tämä tiedote ei ole suoraan tai välillisesti tehty tarjous Australiassa, Kanadassa, Hongkongissa, Japanissa, Uudessa-Seelannissa tai Etelä-Afrikassa, tai millään muulla alueella, jossa tarjous olisi sovellettavan lain vastainen. Osakkeenomistajat, jotka eivät ole Ruotsissa tai Suomessa ja jotka haluavat hyväksyä Ostotarjouksen (kuten määritelty alla) tulee tehdä omat selvityksensä soveltuvasta lainsäädännöstä ja mahdollisista veroseuraamuksista. Osakkeenomistajia kehotetaan tutustumaan ostotarjoukseen kohdistuviin rajoituksiin kohdassa ”Tärkeää tietoa” tämän tiedotteen lopussa sekä tarjousasiakirjassa. Yhdysvalloissa olevia osakkeenomistajia kehotetaan myös katsomaan osio ”Tietoja osakkeenomistajille Yhdysvalloissa” tämän tiedotteen lopussa ja tarjousasiakirjassa. LEHDISTÖTIEDOTE 23.6.2021 Palace Bidco Oy (“WSIP Bidco”), joka on West Street Global Infrastructure Partners IV, L.P.:n (“WSIP”) lukuun perustettu ja sen välillisesti kokonaan omistama yksityinen osakeyhtiö, julkisti 17.5.202

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom